Excipient for Inhalation

Abstract Background/Objectives: The development of dry powder formulations for pulmonary delivery of therapeutic antibodies requires careful stabilization strategies to preserve...

Abstract Lower respiratory tract infections (LRTIs) constitute the fourth leading cause of mortality worldwide, resulting in over two million deaths...

Abstract Dry Powder Inhaler (DPI) formulations generally consist of drug particles with a size between 1 and 5 µm, ideal for...

Our Mineral Salts in low endotoxin quality are produced under stringent GMP standards including low endotoxin process water. This unique...

Abstract Magnesium stearate (MgSt) has been used as a force control agent (FCA) to enhance the aerosol performance of carrier-based...

Abstract There is growing demand for simplified collection of the fine particle dose (FPD, mass of particles less than 5 µm...

Abstract Aerosolized lipid nanoparticles (LNPs) delivering mRNA are an attractive strategy for use in local, inhalable therapy to treat patients...

Abstract Background/Objectives: The integration of machine learning (ML) and artificial intelligence (AI) has revolutionized the pharmaceutical industry by improving drug...

Abstract Pediatric patients are at increased risk of exposure to potentially harmful excipients when receiving off-label medicinal products primarily formulated...

Abstract Pulmonary drug delivery is a form of local targeting to the lungs in patients with respiratory disorders like cystic...